The Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) drugs in development market research report provides comprehensive information on the therapeutics under development for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) by 11 companies/universities/institutes. The top development phase for Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) is preclinical with four drugs in that stage. The Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline products market are: Neurocrine Biosciences, H. Lundbeck and Spruce Biosciences.
The key targets in the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline products market include Corticotropin Releasing Factor Receptor 1, Adrenocorticotropic Hormone Receptor, and Corticotropin Releasing Factor Receptor 2.
The key mechanisms of action in the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline product include Corticotropin Releasing Factor Receptor 1 Antagonist with three drugs in Pre-Registration. The Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline products include three routes of administration with the top ROA being Oral and four key molecule types in the Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) pipeline products market including Small Molecule, and Monoclonal Antibody.
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome) overview
Congenital adrenal hyperplasia (CAH) is an autosomal recessive disease emerging from mutations of genes for enzymes that lead to the biochemical steps of production of glucocorticoids, mineralocorticoids, or sex steroids from cholesterol by the adrenal glands. This condition involves the excessive or deficient production of sex steroids that can alter the development of primary or secondary sex characteristics in some affected infants, children, or adults. Sometimes, deficient production of mineralocorticoids can lead to severe salt-wasting, increasing neonatal morbidity, and mortality.
For a complete picture of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
